MADRID, August 6, 2010 The Spanish BioindustryAssociation (ASEBIO), in collaboration with the Navarre Society ofDevelopment (SODENA), and the government of Navarre, will host BioSpain 2010(http://www.biospain.org), the biennial international gathering of experts inthe biotechnology sector, in Pamplona from September 29th to October 1st.BioSpain 2010 is honoured to welcome three lecturers of internationalprestige: Mr. Carlos Cordon-Cardo, Vice-Chair of Pathology & Professor,Columbia University; Mr. Larry Fritz, President & CEO, CovellaPharmaceuticals Inc. and Life Science Venture Partner, Westfield CapitalManagement Company LP; and Mr. Conny Bogentoft, CEO Karolinska Development AB.
Internationalization will be the highlight of BioSpain this year - over160 companies have already confirmed their participation in the tradeexhibition area, a 33% increase on BioSpain 2008.
BioSpain 2010 will feature an extensive program of breakout sessionsaddressing the most relevant topics in the current biotech scenario,including:
As on previous occasions, BioSpain 2010 will also host the scientificconference organised by the Spanish Society of Biotechnology (SEBIOT), Biotec2010.
An international round-table called "Opportunities and Challenges inGlobal Biomarkets," has also been confirmed. Its main aim is to discuss thepresent state of the biotechnological industry, its development, and itsfuture prospects.
One of the most attractive aspects of BioSpain 2010 is the opportunityfor networking, with over 1,200 delegates from 650 companies & institutionsexpected to attend.
Furthermore, the investors' forum seeks to find new financing sources forfuture entrepreneurial projects. 30 companies will present their businessplan to an audience of experts and investors, including representatives ofMerck & Co, Bay City Capital, La Caixa, Ysios Capital Partners,GlaxoSmithKline Pharmaceuticals, Forbion Capital Partners, Suanfarma Biotech,McKinsey & Company, and PharmaVentures.
Official sponsors of BioSpain 2010 include Caja de Navarra, The ZeltiaGroup, Genoma Espana, AB Biotics, Genetrix, Merck, and ICEX.- Bioenergy - Orphan Drugs & Rare Diseases - Alzheimer's and other neurodegenerative diseases: "What is the Spanish industry doing to develop new drugs?" - Protein Production & Biosimilars - Bioinformatics solutions for genomics: from sequences to Biotechnology and Biomedicine - Alternative Equity Market for Growth Companies - Venture Capital - Biotech's Next Big Thing? - Joint Technology Cooperation Projects between Spain and other countries: Eureka & Canadeka - International Technology Commercialization: The Challenges of US-European Public-Private Partnerships.